OTTAWA, Nov. 29, 2017 /CNW/ - Annidis Corporation (TSX Venture: RHA) ("Annidis" or the Company") announces that it has granted an aggregate of 5,120,000 options to employees and consultants of the Corporation. Each option entitles the holder to acquire one common share in the capital of the Corporation at an exercise price of $0.025. These options will expire on November 28, 2022.
About Annidis Corporation
Annidis (TSX-V: RHA) develops and markets imaging technologies to eye care professionals. It is a North American based company founded on scientific concepts emerging from a decade of research and development by the Annidis team in consultation with respected eye care professionals in Canada, the United States and China. The Annidis RHA™ is a non-invasive ocular pathology management system that integrates advanced multi-spectral imaging with analytic software for early detection and management of ocular pathologies such as glaucoma, age-related macular degeneration, and diabetic retinopathy. The Company distributes its systems in Canada, United States and, through a distributor and major shareholder, in China.
This news release may contain "forward-looking information" within the meaning of applicable Canadian securities legislation. Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope", and "continue" (or the negative thereof), and words and expressions of similar import are intended to identify forward-looking statements. Certain material factors or assumptions are implied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Factors that could cause results to vary include those identified in the Corporation's filings with Canadian securities regulatory authorities, as well as the applicability of patents and proprietary technology; the outcome of pending corporate transactions; possible patent ligation; regulatory approval of products in development; changes in government regulation or regulatory approval processes; government and third party reimbursement; dependence on strategic partnerships; intensifying competition; rapid technological change in the industry; anticipated future losses; the ability to access capital; and the ability to attract and retain key personnel. All forward-looking information presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Corporation does not undertake to update any forward-looking statements; such statements speak only as of the date made.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Annidis Corporation
For further information: Gerald Slemko, Chairman, Annidis Corporation, 613.596.1800, firstname.lastname@example.org